ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0761

Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group

Nilasha Ghosh1, Nina Couette2, Wouter van Binsbergen3, Sophia Weinmann4, Bridget Jivanelli1, Beverley Shea5, Anne Bass6, Karolina Benesova7, Clifton O. Bingham III8, Cassandra Calabrese9, Laura C. Cappelli10, Karmela Kim Chan1, Ernest Choy11, Dimitrios Daoussis12, Susan Goodman1, Marie Hudson13, Shahin Jamal14, Jan Leipe15, Maria A. Lopez-Olivo16, Maria Suarez-Almazor17, Conny van der Laken18, Alexa Meara19, David Liew20 and Marie Kostine21, 1Hospital for Special Surgery, New York, NY, 2Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, 3Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL, Amsterdam, Netherlands, 4Department of Rheumatology & Immunology, Duke University, Durham, NC, 5School of Epidemiology and Public Health, University of Ottawa, Ottawa, 6Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 7University Hospital Heidelberg, Heidelberg, Germany, 8Johns Hopkins University, Baltimore, MD, 9Cleveland Clinic Foundation, Cleveland Heights, OH, 10Johns Hopkins School of Medicine, Baltimore, MD, 11Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 12Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece, 13McGill University, Montréal, QC, Canada, 14University of British Columbia, Vancouver, BC, Canada, 15Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, 16The University of Texas, MD Anderson Cancer Center, Houston, TX, 17MD Anderson Cancer Center, Houston, TX, 18Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, 19The Ohio State University Wexner Medical Center, Columbus, OH, 20Austin Health, Heidelberg, Australia, 21Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France

Meeting: ACR Convergence 2022

Keywords: Inflammation, OMERACT, Outcome measures, Polymyalgia Rheumatica (PMR), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases, such as RA, spondyloarthritis and PMR, may not be appropriate. In this study, we aimed to collate clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set ­of outcome domains.

Methods: As the initial step of the OMERACT core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provided both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Publications were sorted into groups based on the clinical characterization of the disease. Outcome domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter.

Results: We identified 69 publications (Figure 1) which were sorted into seven groups based on clinical descriptors of arthritis/PMR (Table 1). At least one rheumatologist was a co-author in 41 (59%) publications. Over a third of these publications utilized non-specific clinical diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number (n=12 publications), the distribution, size and/or names of specific joints affected (n=17 publications), while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis (n=9 publications). Outcomes used for ICI-IA and ICI-PMR are listed in Figure 2. Most distinct outcome domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 publications described the subsequent response. Unique to this population, tumor response was an outcome domain used in 32 publications.

Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. Among outcomes, there were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use. Assembling classification criteria specific to ICI-induced IA and PMR in addition to gaining eventual consensus achievement of core areas and domains are next steps in order to study and effectively treat these conditions.

Supporting image 1

Flow diagram for scoping review study identification

Supporting image 2

Clinical characterization categories of ICI-induced inflammatory arthritis/PMR

Supporting image 3

ICI-induced inflammatory arthritis and PMR outcomes mapped to core areas and domains


Disclosures: N. Ghosh, GoodRx, Musculo; N. Couette, None; W. van Binsbergen, Bristol-Myers Squibb(BMS); S. Weinmann, None; B. Jivanelli, None; B. Shea, None; A. Bass, None; K. Benesova, Abbvie, BMS, Gilead/Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Roche, Viatris, Gilead/Galapagos, Novartis, Abbvie, Novartis; C. Bingham III, AbbVie, Janssen, Pfizer, Sanofi, Bristol Myers Squibb, Eli Lilly; C. Calabrese, Sanofi, Astrazenica; L. C. Cappelli, Bristol-Myers Squibb(BMS); K. Chan, None; E. Choy, AbbVie, Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Regeneron, R-Pharm, Gilead, Eli Lilly, Janssen, Chugai Pharma, Biocon, Bristol-Myers Squibb (BMS), Galapagos, Amgen, Celgene, ObsEva, Inmedix, Merck Serono, Novimmune, Sanofi, SynAct Pharma, UCB; D. Daoussis, None; S. Goodman, Novartis, UCB; M. Hudson, Bristol-Myers Squibb(BMS), Boehringer-Ingelheim, Mallinckrodt; S. Jamal, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Eli Lilly, Merck/MSD, Pfizer, Janssen, Roche, UCB; J. Leipe, None; M. Lopez-Olivo, None; M. Suarez-Almazor, Eli Lilly, Pfizer, Celgene, ChemoCentryx, Gilead; C. van der Laken, None; A. Meara, None; D. Liew, None; M. Kostine, Bristol-Myers Squibb(BMS), Merck/MSD, Novartis, Janssen, Biogen.

To cite this abstract in AMA style:

Ghosh N, Couette N, van Binsbergen W, Weinmann S, Jivanelli B, Shea B, Bass A, Benesova K, Bingham III C, Calabrese C, C. Cappelli L, Chan K, Choy E, Daoussis D, Goodman S, Hudson M, Jamal S, Leipe J, Lopez-Olivo M, Suarez-Almazor M, van der Laken C, Meara A, Liew D, Kostine M. Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identification-of-outcome-domains-in-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-and-polymyalgia-rheumatica-a-scoping-review-by-the-omeract-irae-working-group/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-outcome-domains-in-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-and-polymyalgia-rheumatica-a-scoping-review-by-the-omeract-irae-working-group/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology